Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
$0.12
$0.16
$1.57
$763K4.024,068 shsN/A
Endologix, Inc. stock logo
ELGX
Endologix
$0.07
$0.03
$0.22
$7.10
$1.41M0.731.28 million shs85,372 shs
PAVmed Inc. stock logo
PAVM
PAVmed
$0.60
+1.0%
$0.65
$0.55
$1.90
$10.21M1.06136,075 shs19,874 shs
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
$31.65
-0.2%
$30.34
$5.17
$39.50
$270.78M1.24145,744 shs21,863 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
0.00%0.00%0.00%-99.33%-99.88%
Endologix, Inc. stock logo
ELGX
Endologix
0.00%0.00%0.00%0.00%0.00%
PAVmed Inc. stock logo
PAVM
PAVmed
0.00%-0.50%-5.46%+0.34%-15.68%
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
0.00%+5.68%+13.85%+3.20%+3,164,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Endologix, Inc. stock logo
ELGX
Endologix
N/AN/AN/AN/AN/AN/AN/AN/A
PAVmed Inc. stock logo
PAVM
PAVmed
3.9509 of 5 stars
3.55.00.04.30.00.01.9
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
0.00
N/AN/AN/A
Endologix, Inc. stock logo
ELGX
Endologix
0.00
N/AN/AN/A
PAVmed Inc. stock logo
PAVM
PAVmed
3.00
Buy$19.003,082.58% Upside
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SNWV, ARTH, PAVM, and ELGX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/6/2025
PAVmed Inc. stock logo
PAVM
PAVmed
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$19.50 ➝ $19.00
4/21/2025
PAVmed Inc. stock logo
PAVM
PAVmed
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$19.00 ➝ $19.50
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
$80K0.00N/AN/A($2.43) per share0.00
Endologix, Inc. stock logo
ELGX
Endologix
$143.37M0.01N/AN/A$3.56 per share0.02
PAVmed Inc. stock logo
PAVM
PAVmed
$1.99M5.12N/AN/A($0.92) per share-0.65
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
$32.63M8.30N/AN/A($1.49) per share-21.24
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
-$6.98MN/A0.00N/AN/A-8,257.70%N/A-730.22%8/18/2025 (Estimated)
Endologix, Inc. stock logo
ELGX
Endologix
-$64.76M-$2.19N/AN/AN/A-44.65%-63.96%-13.26%N/A
PAVmed Inc. stock logo
PAVM
PAVmed
$39.79M$0.710.84N/AN/A3,711.54%N/A-42.29%8/12/2025 (Estimated)
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
-$31.37M-$4.56N/AN/A-89.86%N/A-145.76%N/A

Latest SNWV, ARTH, PAVM, and ELGX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2025Q1 2025
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
N/A-$0.66N/A-$0.66N/A$9.34 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/AN/AN/AN/AN/A
Endologix, Inc. stock logo
ELGX
Endologix
N/AN/AN/AN/AN/A
PAVmed Inc. stock logo
PAVM
PAVmed
N/AN/AN/AN/AN/A
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/A
0.10
0.01
Endologix, Inc. stock logo
ELGX
Endologix
0.29
0.39
0.28
PAVmed Inc. stock logo
PAVM
PAVmed
N/A
0.37
0.37
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
N/A
0.40
0.28

Institutional Ownership

CompanyInstitutional Ownership
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
6.91%
Endologix, Inc. stock logo
ELGX
Endologix
51.61%
PAVmed Inc. stock logo
PAVM
PAVmed
19.93%
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
42.53%

Insider Ownership

CompanyInsider Ownership
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
4.50%
Endologix, Inc. stock logo
ELGX
Endologix
1.30%
PAVmed Inc. stock logo
PAVM
PAVmed
7.30%
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
36.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
104.74 million4.53 millionNot Optionable
Endologix, Inc. stock logo
ELGX
Endologix
52819.17 millionN/AOptionable
PAVmed Inc. stock logo
PAVM
PAVmed
9017.09 million15.85 millionOptionable
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
408.56 million5.43 millionN/A

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Arch Therapeutics stock logo

Arch Therapeutics OTCMKTS:ARTH

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.

Endologix stock logo

Endologix NASDAQ:ELGX

Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system. It also provides endovascular aneurysm sealing system (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, the company offers proximal aortic extensions and limb extensions, which allow physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. It sells its products through direct sales force, and a network of third party distributors and agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.

PAVmed stock logo

PAVmed NASDAQ:PAVM

$0.60 +0.01 (+1.02%)
Closing price 07/3/2025 03:54 PM Eastern
Extended Trading
$0.60 0.00 (0.00%)
As of 07/3/2025 04:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

Sanuwave Health stock logo

Sanuwave Health NASDAQ:SNWV

$31.65 -0.07 (-0.22%)
As of 07/3/2025 01:00 PM Eastern

SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.